TuHURA Biosciences, Inc./NV
Nasdaq · Healthcare · Pharmaceutical Preparations · Tampa, FL
HURA chart
What traders are saying about $HURA
Latest postsTuHURA Biosciences, Inc./NV news
- TuHURA Reports Early Responses in Deep-Seated Merkel Cell Cancer Study
marketbeat.com ·
- TuHURA Biosciences, Inc. (HURA) stock price, news, quote and history
Yahoo Finance Singapore ·
- TuHURA Biosciences Provides First Look at Data from its Open-Label Study of IFx-2.0 as an Adjunctive Therapy to Keytruda® in First Line Treatment of Patients with Deep Seated Metastatic Merkel Cell Carcinoma
Yahoo Finance ·
- Preliminary results: all 3 patients in a cancer study had tumors shrink; responses were ongoing at six months.
Stock Titan ·
- TuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025
Yahoo Finance ·
- TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology
Yahoo Finance ·
- TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers
Yahoo Finance ·
- TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Yahoo Finance ·
- HURA: Milestone Progression Over Next 12 Months
Yahoo Finance ·
- TuHURA Biosciences Highlights Phase III IFx Push, AML Trial Plans at Canaccord
marketbeat.com ·
- TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
Yahoo Finance ·
- TuHURA Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference
Yahoo Finance ·
TuHURA Biosciences, Inc./NV key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | – |
| Net income | -$31.0M | -$23.0M | -$15.0M | -$22.7M |
| Diluted EPS | $-0.63 | $-1.21 | $-2.47 | – |
| Total assets (year end) | $27.4M | $20.0M | $4.4M | $9.9M |
| Cash and equivalents (year end) | $3.6M | $12.7M | $3.7M | $4.9M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About TuHURA Biosciences, Inc./NV
- Ticker
- HURA (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Tampa, FL
- Incorporated in
- NV
- Fiscal year end
- December 31
- SEC CIK
- 1498382
- Former names
- Kintara Therapeutics, Inc., DelMar Pharmaceuticals, Inc., Berry Only Inc.
Frequently asked questions
What exchange is TuHURA Biosciences, Inc./NV listed on?
TuHURA Biosciences, Inc./NV trades on the Nasdaq under the ticker symbol HURA.
What industry is TuHURA Biosciences, Inc./NV in?
TuHURA Biosciences, Inc./NV is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is TuHURA Biosciences, Inc./NV headquartered?
TuHURA Biosciences, Inc./NV's business address on file with the SEC is in Tampa, FL.
When does TuHURA Biosciences, Inc./NV's fiscal year end?
TuHURA Biosciences, Inc./NV's fiscal year ends on December 31.
How much revenue did TuHURA Biosciences, Inc./NV report?
TuHURA Biosciences, Inc./NV reported $0 in revenue for calendar year 2025, according to its SEC filings.